☰

James Yuhtyng Chen, M.D. Ph.D. - Publications

Affiliations: 
2009-2016 Stanford University School of Medicine, Palo Alto, CA, United States 
 2018- Medicine Massachusetts General Hospital & Harvard Medical School, Boston, MA, United States 
Area:
Stem Cell Biology
Tree Info Similar researchers PubMed Report error

27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, et al. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discovery. OF1-OF22. PMID 37847741 DOI: 10.1158/2643-3230.BCD-23-0020  0.635
2022 Chen J, Johnson L, McKenna K, Choi T, Duan J, Feng D, Tsai J, Garcia-Martin N, Sompalli K, Maute R, Vyas P, Majeti R, Takimoto C, Liu J, Ramsingh G, et al. MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia. S317-S318. PMID 36163968 DOI: 10.1016/S2152-2650(22)01421-5  0.812
2021 Sakamaki T, Kao KS, Nishi K, Chen JY, Sadaoka K, Fujii M, Takaori-Kondo A, Weissman IL, Miyanishi M. Hoxb5 defines the heterogeneity of self-renewal capacity in the hematopoietic stem cell compartment. Biochemical and Biophysical Research Communications. 539: 34-41. PMID 33418191 DOI: 10.1016/j.bbrc.2020.12.077  0.428
2019 Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, ... ... Chen JY, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/Jco.18.02018  0.669
2019 Takimoto CH, Chao MP, Gibbs C, McCamish MA, Liu J, Chen JY, Majeti R, Weissman IL. The Macrophage "Do not Eat Me" Signal, CD47, Is A Clinically Validated Cancer Immunotherapy Target. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30689700 DOI: 10.1093/Annonc/Mdz006  0.697
2019 Sallman DA, Donnellan WB, Asch AS, Lee DJ, Malki MA, Marcucci G, Pollyea DA, Kambhampati S, Komrokji RS, Elk JV, Lin M, Agoram B, Chen JY, Volkmer J, Takimoto CHM, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. Journal of Clinical Oncology. 37: 7009-7009. DOI: 10.1200/Jco.2019.37.15_Suppl.7009  0.492
2019 Marjon KD, Chen JY, Duan J, Choi TS, Sompalli K, Feng D, Mata O, Chen S, Kean L, Chao MM, Chao M, Takimoto CH, Agoram B, Dunbar CE, Majeti R, et al. An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates Blood. 134: 4428-4428. DOI: 10.1182/Blood-2019-131490  0.797
2019 Maute RL, Chen JY, Marjon KD, Duan J, Choi T, Chao M, Takimoto CH, Agoram B, Volkmer J. Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab Blood. 134: 5229-5229. DOI: 10.1182/Blood-2019-127526  0.794
2018 Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/Nejmoa1807315  0.71
2018 Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84. PMID 29180808 DOI: 10.1038/S41590-017-0004-Z  0.643
2018 Advani RH, Flinn I, Popplewell L, Forero-Torres A, Bartlett NL, Ghosh N, Kline JP, Tran T, Lynn J, Chen JY, Agoram B, Huang J, Takimoto CHM, Chao M, Smith SM. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Journal of Clinical Oncology. 36: 7504-7504. DOI: 10.1200/Jco.2018.36.15_Suppl.7504  0.394
2018 Sikic BI, Lakhani NJ, Patnaik A, Shah S, Chandana SR, Rasco DW, Colevas AD, O'Rourke TJ, Papadopoulos KP, Fisher GA, Chao M, Agoram B, Chen JY, Huang J, Axt M, et al. A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 3002-3002. DOI: 10.1200/Jco.2018.36.15_Suppl.3002  0.7
2018 Feng D, Gip P, McKenna KM, Zhao F, Mata O, Choi TS, Duan J, Sompalli K, Majeti R, Weissman IL, Takimoto CH, Chao MP, Chen JY, Liu J, Volkmer J. Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia Blood. 132: 2729-2729. DOI: 10.1182/Blood-2018-99-120170  0.795
2017 Szade KT, Gulati GS, Chan CKF, Kao KS, Miyanishi M, Marjon K, Sinha R, George B, Chen JY, Weissman I. Where hematopoietic stem cells live - the bone marrow niche. Antioxidants & Redox Signaling. PMID 29113449 DOI: 10.1089/Ars.2017.7419  0.763
2016 Chen JY, Miyanishi M, Wang SK, Yamazaki S, Sinha R, Kao KS, Seita J, Sahoo D, Nakauchi H, Weissman IL. Hoxb5 marks long-term haematopoietic stem cells and reveals a homogenous perivascular niche. Nature. 530: 223-7. PMID 26863982 DOI: 10.1038/Nature16943  0.778
2015 Mori Y, Chen JY, Pluvinage JV, Seita J, Weissman IL. Prospective isolation of human erythroid lineage-committed progenitors. Proceedings of the National Academy of Sciences of the United States of America. 112: 9638-43. PMID 26195758 DOI: 10.1182/Blood.V122.21.3418.3418  0.75
2015 Cheah MT, Chen JY, Sahoo D, Contreras-Trujillo H, Volkmer AK, Scheeren FA, Volkmer JP, Weissman IL. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 4725-30. PMID 25825750 DOI: 10.1073/Pnas.1424795112  0.782
2015 Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P, Mitra SS, Weissman IL. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proceedings of the National Academy of Sciences of the United States of America. 112: 2145-50. PMID 25646432 DOI: 10.1073/Pnas.1424907112  0.806
2015 Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Seita J, Vincent-Tompkins J, Wearda T, Lu WJ, Senarath-Yapa K, Chung MT, Marecic O, Tran M, et al. Identification and specification of the mouse skeletal stem cell. Cell. 160: 285-98. PMID 25594184 DOI: 10.1016/J.Cell.2014.12.002  0.785
2013 Miyanishi M, Mori Y, Seita J, Chen JY, Karten S, Chan CK, Nakauchi H, Weissman IL. Do pluripotent stem cells exist in adult mice as very small embryonic stem cells? Stem Cell Reports. 1: 198-208. PMID 24052953 DOI: 10.1016/J.Stemcr.2013.07.001  0.798
2013 Chan CK, Lindau P, Jiang W, Chen JY, Zhang LF, Chen CC, Seita J, Sahoo D, Kim JB, Lee A, Park S, Nag D, Gong Y, Kulkarni S, Luppen CA, et al. Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 12643-8. PMID 23858471 DOI: 10.1073/Pnas.1310212110  0.792
2012 Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, et al. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Stem Cells (Dayton, Ohio). 30: 1064-75. PMID 22415968 DOI: 10.1002/Stem.1081  0.315
2011 Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Research. 71: 5569-78. PMID 21730024 DOI: 10.1158/0008-5472.Can-10-2805  0.32
2011 Guo W, Schubbert S, Chen JY, Valamehr B, Mosessian S, Shi H, Dang NH, Garcia C, Theodoro MF, Varella-Garcia M, Wu H. Suppression of leukemia development caused by PTEN loss. Proceedings of the National Academy of Sciences of the United States of America. 108: 1409-14. PMID 21212363 DOI: 10.1073/Pnas.1006937108  0.498
2008 Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y, Yeh JE, Chen JY, Iruela-Arispe ML, Varella-Garcia M, Wu H. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 453: 529-33. PMID 18463637 DOI: 10.1038/Nature06933  0.487
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  0.341
1998 Manodori AB, Matsui NM, Chen JY, Embury SH. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood. 92: 3445-3454. DOI: 10.1182/Blood.V92.9.3445.421K24_3445_3454  0.371
Show low-probability matches.